<p>Formycon AG has received approval from the U.S. Food and Drug Administration (FDA) for Nufymco®, an interchangeable Ranibizumab biosimilar to Lucentis®, for all approved indications in the United States. The regulatory approval was granted following the successful review of the Biologics License Application (BLA). Zydus Lifesciences Limited has been named as the commercialization partner for Nufymco® in the US market. This milestone strengthens Formycon’s presence in the US and highlights the company’s leadership in the development of high-quality biosimilars. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2250924_de), on December 23, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

<p>Formycon AG has received FDA approval for Nufymco®, a biosimilar to Lucentis®, for all approved indications in the US. Zydus Lifesciences Limited will commercialize Nufymco® in the US market. This approval strengthens Formycon’s presence in the US biosimilar market.</p>

FDA Approves Formycon AG’s Nufymco Biosimilar for US Market